203 related articles for article (PubMed ID: 32654072)
1. Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany.
Basic E; Kappel M; Misra A; Sellner L; Ratsch BA; Ostwald DA
Eur J Health Econ; 2020 Dec; 21(9):1351-1361. PubMed ID: 32654072
[TBL] [Abstract][Full Text] [Related]
2. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
3. A U.S. Cost Analysis of Triplet Regimens for Patients with Previously Treated Multiple Myeloma.
Hollmann S; Moldaver D; Goyert N; Grima D; Maiese EM
J Manag Care Spec Pharm; 2019 Apr; 25(4):449-459. PubMed ID: 30917078
[TBL] [Abstract][Full Text] [Related]
4. Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma.
DerSarkissian M; Cranmer H; Dabora J; Bocharova I; Cherepanov D; Cheng M; Bhak RH; Duh MS
Hematology; 2023 Dec; 28(1):2156731. PubMed ID: 36607147
[TBL] [Abstract][Full Text] [Related]
5. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.
Davies F; Rifkin R; Costello C; Morgan G; Usmani S; Abonour R; Palumbo A; Romanus D; Hajek R; Terpos E; Cherepanov D; Stull DM; Huang H; Leleu X; Berdeja J; Lee HC; Weisel K; Thompson M; Boccadoro M; Zonder J; Cook G; Puig N; Vela-Ojeda J; Farrelly E; Raju A; Blazer M; Chari A
Ann Hematol; 2021 Sep; 100(9):2325-2337. PubMed ID: 33970288
[TBL] [Abstract][Full Text] [Related]
6. Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma.
Ailawadhi S; DerSarkissian M; Duh MS; Lafeuille MH; Posner G; Ralston S; Zagadailov E; Ba-Mancini A; Rifkin R
Clin Ther; 2019 Mar; 41(3):477-493.e7. PubMed ID: 30773308
[TBL] [Abstract][Full Text] [Related]
7. Estimating the Costs of Therapy in Patients with Relapsed and/or Refractory Multiple Myeloma: A Model Framework.
Roy A; Kish JK; Bloudek L; Siegel DS; Jagannath S; Globe D; Kuriakose ET; Migliaccio-Walle K
Am Health Drug Benefits; 2015 Jun; 8(4):204-15. PubMed ID: 26157542
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Jakubowiak AJ; Campioni M; Benedict Á; Houisse I; Tichy E; Giannopoulou A; Aggarwal SK; Barber BL; Panjabi S
J Med Econ; 2016 Nov; 19(11):1061-1074. PubMed ID: 27224006
[TBL] [Abstract][Full Text] [Related]
9. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States.
Sanchez L; Chari A; Cheng M; Cherepanov D; DerSarkissian M; Huang F; Stull DM; Dabora J; Young M; Noga SJ; Pi S; Zhang M; Banatwala A; Duh MS; Ailawadhi S
J Manag Care Spec Pharm; 2023 Nov; 29(11):1205-1218. PubMed ID: 37776124
[No Abstract] [Full Text] [Related]
10. Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma.
Goudarzi Z; Shahtaheri RS; Najafpour Z; Hamedifar H; Ebrahimi H
Cost Eff Resour Alloc; 2024 Feb; 22(1):17. PubMed ID: 38419054
[TBL] [Abstract][Full Text] [Related]
11. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
[TBL] [Abstract][Full Text] [Related]
12. Patient Characteristics and Outcomes of Relapsed/Refractory Multiple Myeloma in Patients Treated with Proteasome Inhibitors in Germany.
Steinmetz HT; Singh M; Lebioda A; Gonzalez-McQuire S; Rieth A; Schoehl M; Poenisch W
Oncol Res Treat; 2020; 43(9):449-459. PubMed ID: 32694243
[TBL] [Abstract][Full Text] [Related]
13. Healthcare resource utilization with ixazomib or placebo plus lenalidomide-dexamethasone in the randomized, double-blind, phase 3 TOURMALINE-MM1 study in relapsed/refractory multiple myeloma.
Hari P; Lin HM; Zhu Y; Berg D; Richardson PG; Moreau P
J Med Econ; 2018 Aug; 21(8):793-798. PubMed ID: 29741409
[TBL] [Abstract][Full Text] [Related]
14. A budget impact analysis of lenalidomide in multiple myeloma Egyptian patients.
Elsisi GH; Carapinha JL; Afify R; Elmoty MA; Khalaf M
J Med Econ; 2020 Oct; 23(10):1168-1175. PubMed ID: 32669063
[TBL] [Abstract][Full Text] [Related]
15. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Chari A; Martinez-Lopez J; Mateos MV; Bladé J; Benboubker L; Oriol A; Arnulf B; Rodriguez-Otero P; Pineiro L; Jakubowiak A; de Boer C; Wang J; Clemens PL; Ukropec J; Schecter J; Lonial S; Moreau P
Blood; 2019 Aug; 134(5):421-431. PubMed ID: 31113777
[TBL] [Abstract][Full Text] [Related]
17. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
Raab MS; Engelhardt M; Blank A; Goldschmidt H; Agis H; Blau IW; Einsele H; Ferstl B; Schub N; Röllig C; Weisel K; Winderlich M; Griese J; Härtle S; Weirather J; Jarutat T; Peschel C; Chatterjee M
Lancet Haematol; 2020 May; 7(5):e381-e394. PubMed ID: 32171061
[TBL] [Abstract][Full Text] [Related]
18. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.
Campioni M; Agirrezabal I; Hajek R; Minarik J; Pour L; Spicka I; Gonzalez-McQuire S; Jandova P; Maisnar V
Eur J Health Econ; 2020 Mar; 21(2):219-233. PubMed ID: 31673898
[TBL] [Abstract][Full Text] [Related]
19. Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal.
Armoiry X; Connock M; Tsertsvadze A; Cummins E; Melendez-Torres GJ; Royle P; Clarke A
Pharmacoeconomics; 2018 Sep; 36(9):1073-1081. PubMed ID: 29582405
[TBL] [Abstract][Full Text] [Related]
20. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]